IN
Item 9 Labs Corp.
INLB · OTC
$0.00 +0.00% (+$0.00)
Market Cap $70.2K
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
3/9Valuation
100 /100
Cheap P/S 0.00x
P/B 0.00x
P/E N/A
Growth
100 /100
Growing Rev. growth 63.98%
Book val. growth 102.51%
EPS growth N/A
Profitability
13 /100
Weak Gross margin 33.61%
Net margin 143.14%
Op. margin 106.01%
Quality
3 /100
Poor ROIC 25.60%
ROA 28.12%
Asset turnover 0.20x
Debt
61 /100
Moderate Debt/Equity 0.45x
Current ratio 0.09x
Int. coverage -3.86x
Stability
1 /100
Unstable Beta 0.14x
Rev. volatility 86.24%
EPS volatility 85.31%
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na INLB
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Jeffrey I. Rassas
Employees
97
Headquarters
Phoenix
Nadcházející události
02 PRO
Earnings
Upcoming earnings report